Oniki Hideyuki, Fujii Koji, Kansui Yasuo, Goto Kenichi, Iida Mitsuo
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
J Hypertens. 2006 Feb;24(2):331-8. doi: 10.1097/01.hjh.0000200518.34980.cc.
Diabetes mellitus is an important risk factor for cardiovascular diseases, and vasodilator dysfunction may contribute to vascular complications in diabetes. We previously demonstrated that the angiotensin II receptor blocker (ARB) corrected the impaired endothelium-derived hyperpolarizing factor (EDHF)-mediated arterial hyperpolarization and relaxation associated with hypertension or aging, partially independently of blood pressure.
To test whether EDHF-mediated, as well as endothelium-independent, relaxations would be altered in arteries from type II diabetic Goto-Kakizaki rats, and whether ARB would correct these alterations.
Goto-Kakizaki rats were treated with either the ARB candesartan or a combination of hydralazine and hydrochlorothiazide for 8 weeks, beginning at 10 weeks of age. Membrane potentials and contractile responses were recorded from the isolated mesenteric arteries.
The two treatments lowered blood pressure comparably. Acetylcholine-induced, EDHF-mediated hyperpolarization and relaxation in mesenteric arteries were markedly impaired in untreated Goto-Kakizaki rats compared with age-matched Wistar rats, and neither ARB nor the combination therapy improved these responses. On the other hand, relaxations to endothelium-derived nitric oxide, assessed in rings precontracted with high potassium solution, were similar among the four groups. Relaxation to the nitric oxide donor sodium nitroprusside and that to levcromakalim, an ATP-sensitive K-channel opener, were also impaired in untreated Goto-Kakizaki rats, and the response to sodium nitroprusside was partially improved in treated Goto-Kakizaki rats.
These findings suggest that EDHF-mediated hyperpolarization and relaxation and endothelium-independent relaxations are both impaired in arteries of type II diabetic rats, and antihypertensive treatment with or without ARB partially corrects endothelium-independent relaxations to the nitric oxide donor but not EDHF-mediated responses.
糖尿病是心血管疾病的重要危险因素,血管舒张功能障碍可能导致糖尿病血管并发症。我们之前证明,血管紧张素II受体阻滞剂(ARB)可纠正与高血压或衰老相关的内皮衍生超极化因子(EDHF)介导的动脉超极化和舒张功能受损,部分独立于血压。
测试II型糖尿病Goto-Kakizaki大鼠动脉中EDHF介导的以及不依赖内皮的舒张功能是否会改变,以及ARB是否会纠正这些改变。
Goto-Kakizaki大鼠从10周龄开始接受ARB坎地沙坦或肼屈嗪与氢氯噻嗪联合治疗8周。从分离的肠系膜动脉记录膜电位和收缩反应。
两种治疗方法降低血压的效果相当。与年龄匹配的Wistar大鼠相比,未经治疗的Goto-Kakizaki大鼠肠系膜动脉中乙酰胆碱诱导的、EDHF介导的超极化和舒张明显受损,ARB和联合治疗均未改善这些反应。另一方面,在高钾溶液预收缩的血管环中评估的对内皮衍生一氧化氮的舒张,在四组中相似。对一氧化氮供体硝普钠的舒张以及对ATP敏感性钾通道开放剂左旋克罗卡林的舒张,在未经治疗的Goto-Kakizaki大鼠中也受损,治疗后的Goto-Kakizaki大鼠对硝普钠的反应部分改善。
这些发现表明,II型糖尿病大鼠动脉中EDHF介导的超极化和舒张以及不依赖内皮的舒张均受损,使用或不使用ARB的抗高血压治疗可部分纠正对一氧化氮供体的不依赖内皮的舒张,但不能纠正EDHF介导的反应。